• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Microbiol . Rapid and Specific Detection of Active SARS-CoV-2 With CRISPR/Cas12a

tetano

Editor, Senior Moderator
Front Microbiol


. 2022 Jan 28;12:820698.
doi: 10.3389/fmicb.2021.820698. eCollection 2021.
Rapid and Specific Detection of Active SARS-CoV-2 With CRISPR/Cas12a


Xinyi Liu[SUP] 1 2 [/SUP], Yanhua Li[SUP] 3 [/SUP], Xin Wang[SUP] 4 [/SUP], Yifan Song[SUP] 5 [/SUP], Lina Wu[SUP] 6 [/SUP], Benyuan Yu[SUP] 7 [/SUP], Xiaodong Ma[SUP] 8 [/SUP], Peixiang Ma[SUP] 9 [/SUP], Ming Liu[SUP] 10 [/SUP], Xingxu Huang[SUP] 2 4 [/SUP], Xinjie Wang[SUP] 1 2 [/SUP]



Affiliations

Abstract

Rapid and sensitive nucleic acid detection of SARS-CoV-2 has contributed to the clinical diagnosis and control of COVID-19. Although detection of virus genomic RNA (gRNA) has been commonly used in clinical diagnosis, SARS-CoV-2 gRNA detection could not discriminate between active infectious virus with remnant viral RNA. In contrast to genomic RNA, subgenomic RNAs (sgRNAs) are only produced when the virus is actively replicating and transcription, detection of sgRNA could be an indication to evaluate infectivity. CRISPR/Cas-based nucleic acid detection methods have been considered potential diagnostic tools due to their intrinsic sensitivity, specificity and simplicity. In this study, to specifically detect active virus replication, we developed a CRISPR-based active SARS-CoV-2 (CRISPR-actCoV) detection strategy by detecting sgRNAs of SARS-CoV-2. CRISPR-actCoV with CRISPR Cas12a-assisted fluorescence reporter system enables detection of sgRNAs at 10 copies in 35 min with high specificity and can be read out with naked eyes. Further, we performed CRISPR-actCoV mediated sgRNA detection in 30 SARS-CoV-2 potentially infected clinical samples, and 21 samples were SARS-CoV-2 sgRNA positive. A quantitative RT-PCR assay was also performed to detect gRNA of SARS-CoV-2 in parallel. Among the 30 clinical samples, 27 samples were gRNA positive. Taken together, CRISPR-actCoV provides an alternative for rapid and accurate detection of active SARS-CoV-2 and has great significance in better response of coronavirus causing epidemic disease.

Keywords: COVID-19; CRISPR-based detection; CRISPR/Cas12a; SARS-CoV-2; virus subgenome.
 
Back
Top Bottom